© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
Surabhi Dangi-Garimella, PhD
Articles
Study Finds HCV Infection Increases 10-Year Risk of Cardiovascular Disease
December 14, 2018
Article
A combined analysis of data gathered from the Canadian Health Measures Survey and the US–National Health and Nutrition Examination Survey found a 2.5% to 3.5% increase in the 10-year risk of cardiovascular disease in patients with a hepatitis C virus (HCV) infection.
McAneny Discusses OCM, Community Practices, and Building the Right Rewards
December 10, 2018
Article
The American Journal of Managed Care® sat down with Barbara McAneny, MD, president of the American Medical Association (AMA), to discuss how the AMA is working to "help create the healthcare system of the future."
Longer-Term JULIET Results Confirm Sustained Response With Tisagenlecleucel in Relapsed/Refractory DLBCL
December 06, 2018
Article
A median 19-month follow-up of the JULIET trial—a single-arm, open-label, multicenter, global, pivotal phase 2 trial of the chimeric antigen receptor-T cell therapy tisagenlecleucel directed against CD19-expressing B cells—has found a 40% complete response and a manageable safety profile in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
HBV Reactivation a Serious Adverse Effect of DAAs in the Treatment of HCV
December 06, 2018
Article
A kidney transplant patient treated with direct-acting antivirals (DAAs) for a chronic hepatitis C virus (HCV) infection showed reactivation of the hepatitis B virus (HBV), which proved fatal. The authors of the report recommend a call to action for including HBV testing as part of the patient’s work-up in transplant recipients who are on immunosuppressants, especially in the context of abnormal liver tests.
iLLUMINATE: Superior PFS With Ibrutinib–Obinutuzumab Even in High-Risk, Untreated CLL/SLL
December 03, 2018
Article
Ibrutinib combined with obinutuzumab had better progression-free survival (PFS) at 30 months than the standard chemoimmunotherapy regimen, chlorambucil plus obinutuzumab, regardless of high-risk genomic features in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who had never been treated.
ASH-EHA Joint Symposium Dives Deep Into the Leukemia–Down Syndrome Connection
December 03, 2018
Article
While several associations between constitutional syndromes, such as Down syndrome, and predisposition to cancers have been recognized, recommendations for surveillance or clear association between the 2 are lacking.
Ibrutinib Alone Better Than Chemoimmunotherapy as Frontline in Older Patients With CLL
December 03, 2018
Article
According to the results of Alliance A041202, an international multicenter phase 3 trial, ibrutinib produces superior progression-free survival (PFS) compared with standard chemoimmunotherapy in older patients with chronic lymphocytic leukemia (CLL) and adding rituximab does not improve the ibrutinib response.